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A novel computational method and generation of mutant 
butyrylcholinesterase for cocaine hydrolysis is provided. The 
method includes molecular modeling a possible BChE 
mutant and conducting molecular dynamics simulations and 
hybrid quantum mechanical/molecular mechanical calcula 
tions thereby providing a screening method of possible BChE 
mutants by predicting which mutant will lead to a more stable 
transition state for a rate determining step. Site-directed 
mutagenesis, protein expression, and protein activity is con 
ducted for mutants determined computationally as being 
good candidates for possible BChE mutants, i.e., ones pre 
dicted to have higher catalytic e?iciency as compared with 
wild-type BChE. In addition, mutants A199S/A328W/ 
Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/ 
A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, 
and A199S/F227A/S287G/A328W/E441D all have 
enhanced catalytic ef?ciency for (—)-cocaine compared with 
wild-type BChE. 
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HIGH-ACTIVITY MUTANTS OF 
BUTYRYLCHOLINESTERASE FOR 
COCAINE HYDROLYSIS AND METHOD OF 
GENERATING THE SAME 
RELATED APPLICATIONS 
This application is a division of and claims bene?t to US. 
patent application Ser. No. 13/449,107, now allowed, which 
is a division of and claims bene?t to US. patent application 
Ser. No. 13/018,641, now issued as US. Pat. No. 8,193,327, 
?led Feb. 1, 201 1, which is a division ofand claims bene?t to 
US. patent application Ser. No. 12/752,920, now issued as 
US. Pat. No. 7,919,082, ?ledApr. 1, 2010, which is a division 
of and claims bene?t to US. patent application Ser. No. 
12/192,394, now issued as US. Pat. No. 7,731,957, ?ledAug. 
15, 2008, which is a division of and claims bene?t to US. 
patent application Ser. No. 11/243,111, now issued as US. 
Pat. No. 7,438,904, ?led Oct. 4, 2005. The contents of which 
are incorporated herein by reference in their entirety. 
GOVERNMENT INTEREST 
Subject matter described herein was made with govem 
ment support under Grant Number R01DA013930 awarded 
by the National Institute on Drug Abuse (NIDA) of the 
National Institutes of Health (NIH). The government has 
certain rights in the described subject matter. 
FIELD OF THE INVENTION 
The present invention relates to butyrylcholinesterase vari 
ant polypeptides, and in particular, butyrylcholinesterase 
mutants having amino acid substitutions. 
BACKGROUND OF THE INVENTION 
Cocaine abuse is a major medical and public health prob 
lem that continues to defy treatment. The disastrous medical 
and social consequences of cocaine addiction, such as violent 
crime, loss in individual productivity, illness and death, have 
made the development of an effective pharmacological treat 
ment a high priority. However, cocaine mediates its reinforc 
ing and toxic effects by blocking neurotransmitter reuptake 
and the classical pharmacodynamic approach has failed to 
yield small-molecule receptor antagonists due to the di?icul 
ties inherent in blocking a blocker. An alternative to receptor 
based approaches is to interfere with the delivery of cocaine 
to its receptors and accelerate its metabolism in the body. 
The dominant pathway for cocaine metabolism in primates 
is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the 
benzoyl ester group (Scheme 1). 
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Scheme 1. Schematic representation of BChE-catalyzed 
hydrolysis at the benzoyl ester group. 
Only 5% of the cocaine is deactivated through oxidation by 
the liver microsomal cytochrome P450 system. Cocaine 
hydrolysis at benzoyl ester group yields ecgonine methyl 
ester, whereas the oxidation produces norcocaine. The 
metabolite ecgonine methyl ester is a biologically inactive 
metabolite, whereas the metabolite norcocaine is hepatotoxic 
and a local anesthetic. BChE is synthesized in the liver and 
widely distributed in the body, including plasma, brain, and 
lung. Extensive experimental studies in animals and humans 
demonstrate that enhancement of BChE activity by adminis 
tration of exogenous enzyme substantially decreases cocaine 
half-life. 
Enhancement of cocaine metabolism by administration of 
BChE has been recognized to be a promising pharmacoki 
netic approach for treatment of cocaine abuse and depen 
dence. However, the catalytic activity of this plasma enzyme 
is three orders-of-magnitude lower against the naturally 
occurring (—)-cocaine than that against the biologically inac 
tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from 
plasma in seconds and prior to partitioning into the central 
nervous system (CNS), whereas (—)-cocaine has a plasma 
half-life of approximately 45-90 minutes, long enough for 
manifestation of the CNS effects which peak in minutes. 
Hence, BChE mutants with high activity against (—)-cocaine 
are highly desired for use in humans. Although some BChE 
mutants with increased catalytic activity over wild-type 
BChE have previously been generated, there exists a need for 
mutant BChE with even higher catalytic activity. Thus, prior 
mutants provide limited enhancement in catalytic activity 
over wild-type BChE. 
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Previous studies such as (a) Masson, P.; Legrand, P.; Bar 
tels, C. E; Froment, M-T.; Schopfer, L. M.; Lockridge, 0. 
Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Fro 
ment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lock 
ridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, 
W.; Altamirano, C. V.; Bartels, C. E; Speirs, R. J.; Cashman, 
J. R.; Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, (d) Duy 
sen, E. G.; Bartels, C. E; Lockridge, O. J. Pharmacol. Exp. 
Ther. 2002, 302, 751, (e) Nachon, E; Nicolet,Y.; Viguie, N.; 
Masson, P.; Fontecilla-Camps, J. C.; Lockridge, 0. Eur. J. 
Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J. 
Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner, 
G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261; 
(g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.; 
Brimijoin, S.; Pang,Y.-P. J. Biol. Chem. 2001, 276, 9330, (h) 
Sun, H.; Shen, M. L.; Pang,Y. P.; Lockridge, O.; Brimijoin, S. 
J. Pharmacol. Exp. Ther. 2002, 302, 710, Sun, H.; Pang,Y. 
P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62, 
220 (hereinafter “Sun et al”); and (j) Zhan, C.-G.; Zheng, E; 
Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter 
“Zhan et al”), herein all incorporated by reference, suggested 
that, for both (—)-cocaine and (+)-cocaine, the BChE-sub 
strate binding involves two different types of complexes: 
non-prereactive and prereactive BChE-substrate complexes. 
Whereas the non-prereactive BChE-cocaine complexes were 
?rst reported by Sun et al, Zhan et al were the ?rst reporting 
the prereactive BChE-cocaine complexes and reaction coor 
dinate calculations, disclosed in Zhan et al. 
It was demonstrated that (—)/(+)-cocaine ?rst slides down 
the substrate-binding gorge to bind to W82 and stands verti 
cally in the gorge between D70 and W82 (non-prereactive 
complex) and then rotates to a position in the catalytic site 
within a favorable distance for nucleophilic attack and 
hydrolysis by S198 (prereactive complex). In the prereactive 
complex, cocaine lies horizontally at the bottom of the gorge. 
The main structural difference between the BChE-(—)-co 
caine complexes and the corresponding BChE-(+)-cocaine 
complexes exists in the relative position of the cocaine methyl 
ester group. Reaction coordinate calculations revealed that 
the rate-determining step of BChE-catalyzed hydrolysis of 
(+)-cocaine is the chemical reaction process, whereas for 
(—)-cocaine the change from the non-prereactive complex to 
the prereactive complex is rate determining. A further analy 
sis of the structural changes from the non-prereactive com 
plex to the prereactive complex reveals speci?c amino acid 
residues hindering the structural changes, providing initial 
clues for the rational design of BChE mutants with improved 
catalytic activity for (—)-cocaine. 
Previous molecular dynamics (MD) simulations of prere 
active BChE-cocaine binding were limited to wild-type 
BChE. Even for the non-prereactive BChE-cocaine complex, 
only one mutant (A328W/Y 332A) BChE binding with (—) 
cocaine was simulated and its catalytic activity for (—)-co 
caine was reported by Sun et al. No MD simulation was 
performed on any prereactive enzyme-substrate complex for 
(—)- or (+)-cocaine binding with a mutant BChE. In addition, 
all previous computational studies of Sun et al and Zhan et al 
of BChE interacting with cocaine were performed based on a 
homology model of BChE when three-dimensional (3D) 
X-ray crystal structure was not available for BChE, as taught 
by Nicolet,Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, 
J. C.; Nachon, F. J. Biol. Chem. 2003, 278, 41141 (hereinafter 
“Nicolet et al”), recently reported 3D X-ray crystal structures 
of BChE. As expected, the structure of BChE is similar to a 
previously published theoretical model of this enzyme and to 
the structure of acetylcholinesterase. 
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The main difference between the experimentally deter 
mined BChE structure and its model was found at the acyl 
binding pocket (acyl loop) that is signi?cantly bigger than 
expected. It is unclear whether the structural difference at the 
acyl binding pocket signi?cantly affect BChE binding with 
(—)-cocaine and (+)-cocaine. Although previous MD simula 
tions of cocaine binding with wild-type BChE and the reac 
tion coordinate calculations point to some amino acid resi 
dues that might need to be mutated for the purpose of 
improving the catalytic activity for (—)-cocaine hydrolysis, it 
remained unknown which exact amino acid mutations will 
result in a BChE with a higher catalytic activity for (—) 
cocaine. 
Computational studies of wild-type BChE and cocaine 
from Sun, et al, based on a “homology model,” suggest that 
the rate-determining step for BChE-catalyzed hydrolysis of 
cocaine is the rotation of the cocaine in the active site of 
BChE. By decreasing the hindrance of the rotation, the rate of 
the hydrolysis may be enhanced. Sun, et al describes creating 
an A328W/Y 332A BChE mutant by: (1) replacing Tyr332 
with Ala, “to reduce the steric hindrance and the 313-313 interac 
tion that impede rotation,” and (2) replacingA1a328 with Trp 
“to provide a cation-n interaction to restore substrate a?inity 
lost in disabling the 313-313 interaction.” 
Sun et al studied the A328W/Y 332A BChE mutant using 
enzyme assays and kinetics. In vitro studies were conducted 
using human plasma and in vivo studies were conducted 
using male Sprague-Dawley rats. The mutant was found to 
have enhanced catalytic properties. The mutant was further 
studied using molecular modeling. The three dimensional 
(3D) structure of A328W/Y 332A was generated from the 
computationally generated 3D model of wild-type BChE and 
changing the relevant residues using commercially available 
software. Cocaine was docked to the catalytic gorge of the 
mutant BChE using other commercially available software. 
The cocaine-enzyme complex was re?ned by molecular 
dynamic simulation. The data generated by the molecular 
modeling studies were consistent with enzyme assays and 
kinetic data. 
It should be noted that all prior computational techniques 
(molecular docking and molecular dynamics simulation) 
used by other researchers are based on an empirical force ?eld 
which cannot be used to perform any necessary reaction 
coordinate calculation for the detailed understanding of the 
complicated catalytic reaction process. As it is well-known, it 
is particularly challenging to model and simulate the detailed 
reaction pathway and predict the kinetics of such an enzy 
matic reaction. 
U.S. Patent Application Publication Nos. 2004/0121970; 
2004/0120939; and 2003/0153062, describe 20+BChE 
mutants, or “variants,” from human and other animals, each 
having from one to six amino acid alterations and increased 
cocaine hydrolysis activity. For example, mutants include 
F227A/A328W; F227A/S287G/A328W; A119S/S287G/ 
A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/ 
287G/A328W and A119S/F227A/S287G/A328W/Y332M. 
The mutants have varying increases in catalytic activity, up to 
100-fold increase relative to wild-type BChE. 
There exists a need in the art for determining which pro 
posed mutant BChEs should have ever increasing catalytic 
activity and for generating those mutants which should have 
enhanced catalytic activity. 
SUMMARY OF THE INVENTION 
The present invention includes ?ve novel human BChE 
mutants that have unexpected increased catalytic e?iciency 
US 8,835,150 B1 
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for cocaine hydrolysis. The mutants have various unique 
amino acid residue substitutions which provide the surprising 
enhanced catalytic activity. These mutants are (1) A199S/ 
A328W/Y332G mutant (SEQ ID NO: 2), which has a 
approximately 65-fold improved catalytic ef?ciency against 
(—)-cocaine; (2) A199S/F227A/A328W/Y332G mutant 
(SEQ ID NO: 8), which has an approximately 148-fold 
improved catalytic ef?ciency against (—)-cocaine; (3) A1 99S/ 
S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has 
an approximately 456-fold improved catalytic ef?ciency 
against (—)-cocaine; (4) A199S/F227A/S287G/A328W/ 
Y332G mutant (SEQ ID NO: 20), which has an approxi 
mately 1.003-fold improved catalytic ef?ciency against (—) 
cocaine; and (5) A199S/F227A/S287G/A328W/E441D 
mutant (SEQ ID NO: 26), which has an approximately 445 
fold improved catalytic ef?ciency against (—)-cocaine. 
In addition, the aforementioned mutant amino acid 
sequences can be truncated without substantially affecting 
the catalytic activity so that amino acid residues 1-67 and 
443-574 can be removed without substantially affecting the 
catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 
and 28 are the amino acid sequences for residue 68-142 
corresponding to mutants 1-5, respectively. In addition, with 
regard to mutants 1-4, it was found that amino acid residues 
before 117 and after 438 could be removed without substan 
tially changing the activity of the mutant enzymes, resulting 
in truncated amino acid sequences having SEQ ID NOS: 6, 
12, 18 and 24, respectively. Finally with regard to mutant 5, 
amino acid residues before 117 and after 441 could be 
removed without substantially changing its activity resulting 
in SEQ ID NO: 30. 
These aforementioned truncated sequences all of with 
similar catalytic activity is based on protein structures. 
Further, the present invention is directed to a novel and 
unique pharmaceutical composition which comprises a 
butyrylcholinesterase variant, namely mutants 1-5, along 
with a suitable pharmaceutical carrier. The pharmaceutical 
composition can be administered to an individual in an effec 
tive amount to lower the patient’s cocaine blood concentra 
tion and in particular (—)-cocaine blood concentration. 
In addition, the present invention is directed to a novel and 
unique method for developing mutants which have enhanced 
catalytic ef?ciency. The generation method includes both a 
computational portion and an experimental portion. With 
regard to the computational portion, a variety of state of the 
art computational techniques including molecular modeling, 
molecular dynamics (MD) simulations and hybrid quantum 
mechanical/molecular mechanical (QM/MM) calculations, 
provide a virtual screening of possible BChE mutants. This 
virtual screening predicts which mutation will lead to a more 
stable transition state for a rate-determining step compared to 
the corresponding separated reactants, i.e., free cocaine and 
free enzyme. The more stable the transition state, the lower 
the energy barrier, and the higher the catalytic ef?ciency. 
Following the computational portion, an experimental test is 
then conducted on the possible mutants of the computation 
portion. The experimental test includes site-directed 
mutagenesis, protein expression, and enzyme activity assay. 
The experimental tests are conducted on mutants which are 
predicted to have a high catalytic ef?ciency against (—)-co 
caine than the wild-type BChE and/or other known BChE 
mutants against (—)-cocaine. Thus, the present method iden 
ti?es or predicts mutants having high catalytic activity for 
cocaine hydrolysis by performing molecular modeling and 
MD simulations on the transition state structures of possible 
mutants of BChE. This method is an improvement over tra 
ditional random-search approaches, which, given the com 
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plex catalytic mechanism of cocaine hydrolysis, makes it 
dif?cult to improve the catalytic activity of BChE for cocaine 
hydrolysis. 
The present invention in one form, concerns a butyrylcho 
linesterase variant peptide comprising an amino acid 
sequence selected from the group consisting of SEQ ID NOS: 
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. 
The present invention in another form thereof concerns a 
nucleic acid molecule comprising a nucleic acid sequence 
which encodes a butyrylcholinesterase variant peptide, the 
nucleic acid sequence selected from the group consisting of 
SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 
and 29. 
The present invention in another form thereof concerns a 
pharmaceutical composition comprising a butyrylcholinest 
erase variant polypeptide comprising an amino acid sequence 
selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable 
pharmaceutical carrier. 
The present invention in another form thereof concerns a 
method for treating a cocaine-induced condition comprising 
administering to an individual an effective amount of butyryl 
cholinesterase variant peptide having an amino acid sequence 
selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood 
cocaine concentration. 
The present invention is another form thereof concerns a 
method for treating a cocaine induced condition comprising 
administering to an individual an effective amount of a phar 
maceutical composition comprising a butyrylcholinesterase 
variant having an amino acid sequence selected from the 
group consisting ofSEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier 
of claim 3 to an individual in an effective amount to lower 
blood cocaine concentration. 
The present invention in yet another form thereof concerns 
a method for generating butyrylcholinesterase mutants. The 
method includes generating an initial structure of the transi 
tion state structure for the rate-determining step of the 
cocaine hydrolysis catalyzed by a possible butyrylcholinest 
erase mutant. A suf?ciently long time molecular dynamics 
simulation is performed on the transition state structure in 
water to have a stable molecular dynamics trajectory. The 
molecular dynamics trajectory is analyzed and the hydrogen 
bonding energies are estimated between the carboxyl oxygen 
of the (—)-cocaine benzyl ester and the oxyanion hole of the 
possible butyrylcholinesterase mutant. If the overall hydro 
gen binding energy between the carboxyl oxygen of the (—) 
cocaine benzyl ester and the possible butyrylcholinesterase 
mutant, in the transition state, is stronger than the overall 
hydrogen binding energy between the carboxyl oxygen of the 
(—)-cocaine benzyl ester and the wild-type butyrylcholinest 
erase, optionally, hybrid quantum mechanical/molecular 
mechanical (QM/MM) geometry optimization is performed 
to re?ne the molecular dynamics-simulated structure, the 
hydrogen binding energies are calculated and the energy bar 
rier is evaluated. Finally, the butyrylcholinesterase mutant is 
generated. 
In various alternative embodiments, the generating an ini 
tial structure of the transition state structure is based on reac 
tion coordinate calculations for the wild-type butyrylcho 
linesterase. The generating butyrylcholinesterase mutant 
includes performing site-directed mutagenesis on a nucleic 
acid sequence which includes wild-type butyrylcholinest 
erase to generate the mutant butyrylcholinesterase nucleic 
acid sequence. Using the mutant butyrylcholinesterase 
nucleic acid sequence, the protein encoded by the mutant 
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nucleic acid sequences is expressed to produce mutant 
butyrylcholinesterase and catalytic activity assay is per 
formed on the mutant butyrylcholinesterase. 
The hybrid quantum mechanical/molecular mechanical 
geometry optimization may include calculating the hydrogen 
binding energies and evaluating the energy barriers only if the 
overall hydrogen binding energy between the carboxyl oxy 
gen of the (—)-cocaine benzyl ester and the possible butyryl 
cholinesterase mutant, in the transition state, is stronger than 
known butyrylcholinesterase mutants against (—)-cocaine. 
In yet another alternative further embodiment, the method 
for generating butyrylcholinesterase mutants further includes 
determining the rate-limiting step in the hydrolysis of (—) 
cocaine by the possible butyrylcholinesterase mutant by con 
ducting molecular dynamics simulations and quantum 
mechanical/ molecular mechanical calculations relating to the 
transition states for other reaction steps between (—)-cocaine 
by the possible butyrylcholinesterase mutant and calculating 
respective energy barriers, thereby establishing which of the 
reaction steps is the rate-determining one. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 are plots of distances in the MD simulation (—) 
cocaine binding with A328W/Y332G BChE versus the simu 
lation time, along with root-mean-square deviation (RMSD) 
in the enzyme-substrate complexes where FIG. 1A represents 
the non-prereactive enzyme-substrate complexes; and FIG. 
1B represents the prereactive enzyme-substrate complexes in 
accordance with the present invention. 
FIG. 2 shows the binding of structures of the simulated 
non-prereactive and prereactive complexes of wild-type 
BChE binding with two entomers of cocaine in which FIG. 
2A depicts BChE (—)-cocaine non-prereactive complex; FIG. 
2B depicts BChE (—)-cocaine prereactive complex, FIG. 2C 
depictes BChE (+)-cocaine non-prereactive complex; and 
FIG. 2D depicts BChE (+)-cocaine prereactive complex. 
FIG. 3A shows the (—)-cocaine rotation in the BChE active 
site for the non-prereactive complex to the prereactive com 
plex hindered by some residues at positions Y332, A328, and 
F329 residues in the non-prereactive complexes which are 
signi?cantly different from the corresponding positions in the 
prereactive complex; and FIG. 3B shows the (+)-cocaine 
rotation in the BChE active site where none of the aforemen 
tioned residues hinders the (+)-cocaine rotation in the BChE 
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active site from the non-prereactive complex to the prereac 
tive complex in accordance with the present invention. 
FIG. 4A depicts the (—)-cocaine rotation in the active site of 
A328W/Y332A; FIG. 4B depicts the (—)-cocaine rotation in 
the active site of A328W/Y332G BChE from the non-preac 
tive complex to the prereactive complex; and FIG. 4C depicts 
the (—)-cocaine rotation in the active site of wild-type BChE. 
FIG. 5A is a plot of the key internuclear distances (in A) 
versus the time in the simulated TSl structure for (—)-cocaine 
hydrolysis catalyzed by A328W/Y 332A; and FIG. 5B for 
Al 99S/A328W/Y332G BChE. 
FIG. 6 is a plot of key internuclear distances (in A) versus 
the time in the simulated TSl structure for (—)-cocaine 
hydrolysis catalyzed by Al 99S/S287G/A328W/Y332G 
BChE. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention has two major improvements over 
the prior art. The ?rst is the presently discovered BChE 
mutants, mutant 1, Al99S/A328W/Y332G; mutant 2, 
Al99S/F227A/A328W/Y332G; mutant 3, A199S/S287G/ 
A328W/Y332G; mutant 4, Al99S/F227A/S287G/A328W/ 
Y332G; and mutant 5, Al99S/F227A/S287G/A328W/ 
E44lD each have a signi?cantly higher catalytic ef?ciency. 
The second improvement is concerning the mutant designing 
or discovering process. 
The BChE mutants 1-5 have full length amino acid 
sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, 
which are encoded by nucleic acid sequences having SEQ ID 
NOS: 1, 7, l3, l9, and 25, respectively. Table 1 summarizes 
the catalytic ef?ciency against (—)-cocaine for the ?ve 
mutants. 
In addition to the full length BChE mutants, the respective 
amino acid sequence can be truncated without substantially 
affecting the respective catalytic activity. With all mutants, 
residues 1-67 and 443-574 can be removed without substan 
tially affecting the catalytic activity of the respective mutant 
BChE. Further, with regard to mutant 1-4, amino acids 1-1 16 
and 439-574 canbe omitted without substantially affecting its 
respective catalytic activity. With regard to mutant 5, amino 
acid residues 1-116 and 442-574 can be omitted without 
substantially affecting its catalytic activity. Table 1 also pro 
vides a summary of amino acid SEQ ID NOS and correspond 
ing nucleic acid SEQ ID NOS for the aforementioned trun 
cated mutant BChE sequences. 
TABLE 1 
Partially 
Truncated Nucleic SEQ ID SEQ ID NO 
Amino Nucleic Amino Acid Sequence NO. for Corresponding SEQ ID NO. Catalytic 
Acid Acid Acid Corresponding To Amino Acid To Amino Acid for Amino Ef?ciency 
Mutant Substi— SEQ ID SEQ ID Amino Acid Residues Residues Acid Residues Against 
Number tuting NO. NO. Residues 68—442 68—442 117-43 8/441 * 117-43 8/441 * (—)—cocaine 
1 A199S/ 1 2 3 4 5 6 65-fold 
A328W/ 
Y332G 
2 A199S/F 7 8 9 10 11 12 148-fold 
227NA 
328W/Y 
332G 
3 A1995/S 13 14 15 16 17 18 456-fold 
287G/A 
328W/Y 
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TABLE 1-continued 
Partially 
Truncated Nucleic SEQ ID SEQ ID NO 
Amino Nucleic Amino Acid Sequence NO. for Corresponding SEQ ID NO. Catalytic 
Acid Acid Acid Corresponding To Amino Acid To Amino Acid for Amino Ef?ciency 
Mutant Substi— SEQ ID SEQ ID Amino Acid Residues Residues Acid Residues Against 
Number tuting NO. NO. Residues 68—442 68—442 117—43 8/441* 117-43 8/441 * (—)—cocaine 
4 A1995/F 19 20 21 22 22 24 1,003-fold 
227NS2 
87G/A3 
28W/Y 3 
32G 
5 A1995/F 25 26 27 28 29 30 445-fold 
227NS2 
87G/A3 
28W/E4 
41D 
(* Amino acid residues 117-438 for mutants 1-4 and resi 
dues 117-441 for mutant 5.) 
The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be 
formulated in a pharmaceutical composition along with a 
suitable pharmaceutical carrier known to one skilled in the 
art. 
The present BChE variant polypeptides can be used in 
treating a cocaine-induced condition by administering to an 
individual, an effective amount of one of the BChE variant 
polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, 28, and 30, to lower blood cocaine concentra 
tion. The BChE variant polypeptide may be administered in 
the form of a pharmaceutical composition in which the BChE 
variant is included with a suitable pharmaceutical carrier. 
Treatment of a cocaine induced condition using one of the 
aforementioned BChE variant polypeptides can be done in 
accordance with Zhan et al., page 2463. 
The preferred dose for administration of a butyrylcho 
linesterase or peptide composition in accordance with the 
present invention is that amount which will be effective in 
lowering (—)-cocaine concentration in a patient’s blood 
stream, and one would readily recognize that this amount will 
vary greatly depending on the nature of cocaine consumed, 
e.g., injected or inhaled, and the condition of a patient. An 
“effective amount” of butyrylcholinesterase mutant or phar 
maceutical agent to be used in accordance with the invention 
is intended to mean a nontoxic but suf?cient amount of the 
agent, such that the desired prophylactic or therapeutic effect 
is produced. Thus, the exact amount of the enzyme or a 
particular agent that is required will vary from subject to 
subject, depending on the species, age, and general condition 
of the subject, the severity of the condition being treated, the 
particular carrier or adjuvant being used and its mode of 
administration, and the like. Similarly, the dosing regimen 
should also be adjusted to suit the individual to whom the 
composition is administered and will once again vary with 
age, weight, metabolism, etc. of the individual. Accordingly, 
the “effective amount” of any particular butyrylcholinest 
erase composition will vary based on the particular circum 
stances, and an appropriate effective amount may be deter 
mined in each case of application by one of ordinary skill in 
the art using only routine experimentation. 
A unique method was used to determine potential BChE 
mutants with projected increased catalytic activity for the 
hydrolysis of cocaine. The method provides a unique 
approach which ?rst models the potential BChE mutant inter 
action with cocaine followed by generating the BChE mutant 
if the predicted model indicates that the BChE variant should 
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have enhanced catalytic activity. The method includes gener 
ating an initial structure of the transition state structure for the 
rate-determining step for the cocaine hydrolysis catalyzed by 
a possible BChE mutant. A suf?ciently long time molecular 
dynamics simulation is performed on the transition state 
structure in water to have a stable molecular dynamics traj ec 
tory. The molecular dynamics trajectory is analyzed and the 
hydrogen binding energies are estimated between the car 
boxyl oxygen of the (—)-cocaine benzoyl ester and the oxya 
nion hole of the possible BChE mutant. If the overall hydro 
gen binding energy between the carboxyl oxygen of the (—) 
cocaine benzoyl ester and the possible BChE mutant, in the 
transition state, is stronger than the overall hydrogen binding 
energy between the carboxyl oxygen of the (—)-cocaine ben 
zoyl ester and the wild-type BChE, hybrid quantum mechani 
cal/molecular mechanical (QM/MM) geometry optimization 
is performed to re?ne the molecular dynamics-simulated 
structure, the hydrogen binding energies are calculated and 
the energy barrier is evaluated. The QM/MM calculations 
make the computational predictions more reliable. Finally, 
the BChE mutant is generated. 
With regard to the molecular dynamics (MD) simulations 
and quantum mechanical/molecular mechanical (QM/MM) 
calculations, the ?rst chemical reaction step of (—)-cocaine 
hydrolysis catalyzed by butyrylcholinesterase (BChE) 
mutants and, when needed, other reaction steps are modeled 
and calculated using molecular dynamics simulations and 
QM/MM calculations. Following this modeling, mutant 
BChE’ s are created using site-directed mutagenesis followed 
by protein expression. The afonnentioned ?ve mutants were 
identi?ed by computational analysis and generated by site 
directed mutagenesis which have signi?cantly enhanced (—) 
cocaine hydrolysis catalytic ef?ciency compared with wild 
type BChE. 
In the present method computational analysis in the form 
of molecular modeling of a potential BChE mutant and MD 
simulations and QM/MM calculations provide virtual screen 
ing of possible BChE mutants which have predicted enhanced 
catalytic activity for (—)-cocaine. For example, the MD simu 
lations and QM/MM calculations predict which mutation will 
lead to a more stable transition state for the rate determining 
step compared to the corresponding separated reagents, i.e., 
free cocaine and free possible mutant BChE, where the more 
stable transition state leads to a lower energy barrier and 
higher predicted catalytic ef?ciency. Only after the computa 
tional analysis predicts enhanced catalytic ef?ciency, is site 
directed mutagenesis conducted on wild-type BChE nucleic 
acid sequence to generate a mutant nucleic acid sequence 
which is then used to express a mutant BChE protein. The 
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mutant BChE protein is then used in catalytic assays to deter 
mine the catalytic e?iciency against (—)-cocaine. 
The use of predictive, computational modeling of the 
present method for identifying mutant BChE candidates and 
the resulting mutant BChE are novel and unexpected over 
prior conventional methods which will now be readily appar 
ent to one of ordinary skill in the art. 
Using the present method, most discovered new mutants 
include a speci?c mutation (Y 332G) on residue #332. No 
prior BChE mutant having the Y332G mutation had ever been 
reported previously; only mutations Y332A and Y332M on 
residue #332 had been tested previously by other researchers. 
Prior to the present invention, there was no reason to expect 
that a mutant includingY332G mutation should be better than 
the corresponding mutant including Y332A mutation or 
Y332M. Thus, the present mutants with a Y332G mutation 
which have enhanced cataltytic activity represent a surprising 
and unexpected result over prior BChE mutants. 
A Y332G mutant (single mutation) was ?rst tested and 
found that the Y332G mutant had a slightly low (or approxi 
mately equal) catalytic ef?ciency than the wild-type. So, only 
an appropriate combination of different mutations on differ 
ent residues could make the enzyme more active. As seen 
below, the prior art did not reveal that any of the particular 
combinations tested was expected to have an improved cata 
lytic ef?ciency. The present method is based on the present 
unique, extensive computational modeling and simulations of 
the detailed catalytic mechanism for both the wild-type BChE 
and the mutants. 
The primary improvement of the present method over the 
prior art is that high-performance computational modeling 
and simulations of the detailed catalytic mechanism are per 
formed, which includes modeling how cocaine binds with 
BChE and the subsequent structural transformation and 
chemical reaction process. The prior art only considered the 
cocaine binding with the enzyme (BChE) and was unable to 
examine the detailed catalytic reaction process after the 
BChE-cocaine binding. When molecular modeling was lim 
ited to studying the BChE-cocaine binding, one could only 
design a mutation to improve the BChE-cocaine binding 
without knowing whether the mutation will also speedup the 
subsequent chemical reaction process or not. 
To overcome the obstacles of prior challenges to using 
computational techniques such as molecular docking and 
molecular dynamics simulation previously used by others 
which were based on an empirical force ?eld which cannot be 
used to perform necessary reaction coordinate calculations 
for the catalytic reaction process, a variety of state-of-the-art 
computational techniques of homology modeling, molecular 
docking, molecular dynamics, quantum mechanics (QM), 
and hybrid quantum mechanics/molecular mechanics (QM/ 
MM) were used for the rational design of the BChE mutants. 
The combined use of these computational techniques, includ 
ing QM and QM/MM, led to the study of the detailed reaction 
coordinate of the BChE-catalyzed hydrolysis of cocaine 
which, for the ?rst time, provided the detailed structures of all 
transition states and intermediates existing in the reaction 
process and the corresponding energetics. These extensive 
computational modeling and simulation studies provided for 
the rational design of possible BChE mutants that not only 
can improve the BChE-cocaine binding, but also can speedup 
the subsequent chemical reaction process. As a result, one can 
now quickly discover the BChE mutants with the signi? 
cantly improved catalytic ef?ciency. 
In addition, to the differences mentioned above, the present 
molecular modeling of the BChE-cocaine binding also differs 
from the prior modeling. The molecular modeling in the prior 
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art considered only one binding mode for each BChE-cocaine 
system, without modeling the possible cocaine rotation in the 
BChE active site after the binding. The present method con 
siders two different binding modes for each BChE-cocaine 
system and the structural transformation between them: non 
prereactive and prereactive BChE-cocaine complexes. The 
present modeling provides more detailed information about 
the BChE-cocaine binding and the subsequent structural 
transformation. 
The present method includes molecular dynamics simula 
tions performed on the cocaine binding with both the wild 
type BChE and the mutants whereas prior molecular dynam 
ics simulations were only performed on the cocaine binding 
with the wild-type BChE. As is shown below in the following 
experiments, the computational prediction could be com 
pletely wrong without directly modeling and simulating 
cocaine binding with the proposed mutants. 
The present invention will now be discussed with regard to 
the following non-limiting examples in the form of experi 
ments which are provided to enhance understanding of the 
present invention but in no way limit its scope or applicability. 
Experiment 1 
Computational Study of Cocaine Binding with 
Wild-Type and Mutant BCHE’s for A328W/Y 332G, 
A328W/Y332A, and A328W/Y332A/Y419S 
A detailed computational study of cocaine binding with 
wild-type and mutant BChE’s starting from the available 
X-ray crystal structure of wild-type BChE was performed. 
The simulated mutants include A328W/Y 332G, A328W/ 
Y332A, and A328W/Y332A/Y419S, as simple geometric 
consideration of the binding site suggests that these mutations 
could be important for changing the (—)-cocaine rotation from 
the non-prereactive complex to the prereactive complex. Wet 
experimental tests were conducted on the catalytic activity of 
these mutants for (—)-cocaine in order to verify the computa 
tional predictions. All of the obtained results clearly demon 
strate that molecular modeling and MD simulations of 
cocaine binding with BChE mutants provide a reliable com 
putational approach to the rational design of high-activity 
mutants of BChE for the (—)-cocaine hydrolysis. 
3D Model of BChE. 
The initial coordinates of human BChE used in the com 
putational studies came from the X-ray crystal structure 
deposited in the Protein Data Bank (pdb code: 1POP). The 
missing residues (D2, D3, E255, D378, D379, N455, L530, 
E531, and M532) in the X-ray crystal structure were built 
using the automated homology modeling tool Modeler dis 
closed by Sali,A.; Blundell, T. L. J. Mol. Biol. 1990, 212 403, 
and Sali, A.; Blundell, T. L. J. Mol. Biol. 1993, 234, 779, 
herein incorporated by reference, and lnsightll software (Ac 
celrys, Inc.) with the default parameters. 
Molecular Docking. 
Molecular docking was performed for each non-prereac 
tive protein-ligand binding complex. The binding site was 
de?ned as a sphere with an approximately 15 A radius around 
the active site residue S198. The amino acid residues included 
in the binding site model are not contiguous in the protein. 
Cocaine, considered as a ligand, was initially positioned at 17 
A in front of S198 of the binding site. Each BChE-cocaine 
binding complex was energy-minimized by using the steepest 
descent algorithm ?rst until the maximum energy derivative 
is smaller than 4 kcal/mol/ A and then the conjugated gradient 
algorithm until the maximum energy derivative is smaller 
than 0.001 kcal/mol/A. The energy minimization was fol 
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lowed by a 300 ps molecular dynamics (MD) simulation at 
T:298 K with a time step of 1 fs. During the energy minimi 
zation and MD simulation, only cocaine and the residues of 
BChE included in the binding site were allowed to move, 
while the remaining part of the protein was ?xed. The energy 
minimization and MD simulation for these processes were 
performed by using the Amber force ?eld implemented in the 
Discoveri3/InsightII calculation engine, disclosed by Cor 
nell, W. D.; Cieplak, P.; Bayl), C. I.; Gould, I. R.; Merz, Jr., K. 
M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. 
W.; Kollman, P. A. J. Am. Chem. Soc. 1995, 117, 5179. The 
non-bonded cut-off method and the dielectric constant were 
set up to group based (12 A cut-off distance) and distance 
dependent, respectively (6:4r) in accordance with Harvey, S. 
C. Proteins 1989, 5, 78-92, herein incorporated by reference. 
Molecular Dynamic Simulation in Water. 
The initial coordinates used in the MD simulation of the 
non-prereactive complexes were determined by using the 
molecular docking procedure described above, whereas the 
initial coordinates used in the MD simulation of the prereac 
tive complexes were obtained from superimposing backbone 
of the X-ray crystal structure to that of the previously dis 
closed simulated prereactive complex of Zhan et al between 
cocaine and a homology model of wild-type BChE. Each 
BChE-cocaine binding complex was neutralized by adding 
two chloride counterions and was solvated in a rectangular 
box of TIP3P water molecules with a minimum solute-wall 
distance of 10 A. The general procedure for carrying out the 
MD simulations in water is similar to that used in our previ 
ously reported other computational studies such as those in 
Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rit 
tenhouse, R.; Omstein, R. L. J. Am. Chem. Soc. 1999, 121, 
7279, (b) Koca, J .; Zhan, C.-G.; Rittenhouse, R.; Omstein, R. 
L. J Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, 
C.-G.; Rittenhouse, R. C.; Omstein, R. L. J. Compul. Chem. 
2003, 24, 368, herein all incorporated by reference. These 
simulations were performed by using the Sander module of 
Amber7 program as taught by Case, D. A.; Pearlman, D. A.; 
Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; 
Simmerling, C. L.; Darden, T.A.; Merz, K. M.; Stanton, R.V.; 
Cheng,A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; 
Radmer, R. J.; Duan,Y.; Pitera, J.; Massova, I.; Seibel, G. L.; 
Singh, U. C.; Weiner, P. K.; Kollman, P. A. (2002),AMBER 7, 
University of California, San Francisco, herein incorporated 
by reference. The solvated system was optimized prior to the 
MD simulation. First, the protein-ligand was frozen and the 
solvent molecules with counterions were allowed to move 
during a 5000-step minimization with the conjugate gradient 
algorithm and a 5 ps MD run at T:300 K. After full relaxation 
and the entire solvated system was energy-minimized, the 
system was slowly heated from T:10 K to T:300 K in 30 ps 
before the production MD simulation for 500 ps. The full 
minimization and equilibration procedure was repeated for 
each mutant. The MD simulations were performed with a 
periodic boundary condition in the NPT ensemble at T:300 K 
with Berendsen temperature coupling and constant pressure 
(P:1 atm) with isotropic molecule-based scaling disclosed in 
Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; 
DiNola, A.; Haak, J. R. J. Comp. Phys. 1984, 81, 3684, herein 
incorporated by reference. The SHAKE algorithm of Ryck 
aert, J. P.; Ciccotti, G.; Berendsen, H. C.J. Comp. Phys. 1977, 
23, 327 (herein incorporated by reference) was applied to ?x 
all covalent bonds containing a hydrogen atom, a time step of 
2 fs was used, and the non-bond pair list was updated every 10 
steps. The pressure was adjusted by isotropic position scaling. 
The particle mesh Ewald (PME) method of Essmann, U.; 
Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Peder 
sen; L. G. J. Chem. Phys. 1995, 98, 10089, herein incorpo 
rated by reference, was used to treat long-range electrostatic 
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interactions.A residue-based cutoff of 10 Awas applied to the 
noncovalent interactions. During the 500 ps production MD 
simulation, the coordinates of the simulated complex were 
saved every 1 ps. 
Molecular docking and MD simulation procedures 
described above were performed to study cocaine binding 
with wild-type BChE and three mutants, i.e., A328W/ 
Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For 
each protein system (wild-type or mutant BChE), the protein 
binding with cocaine was considered in both the non-prere 
active and prereactive enzyme-substrate complexes. 
Most of the MD simulations in water were performed on a 
supercomputer, Superdome (shared-memory, with 4 nodes 
and 256 processors), at the Center for Computational Sci 
ences, University of Kentucky. The other computations were 
carried out on SGI Fuel workstations and a 34-processors 
IBM x335 Linux cluster. 
Experimental Procedure. 
Site-directed mutagenesis of human BChE cDNA was per 
formed by the QuikChange method of Braman, J .; Papworth, 
C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein 
incorporated by reference. Mutations were generated from 
wild-type human BChE in a pRc/CMV expression plasmid in 
accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; 
Speirs, R. J.; Cashman, J. R.; Lockridge, 0. Mol. Pharmacol. 
1999, 55, 83, all herein incorporated by reference, kindly 
provided by Dr. Lockridge at University of Nebraska Medical 
Center. Using plasmid DNA as template and primers with 
speci?c base-pair alterations, mutations were made by poly 
merase chain reaction with Pfu DNA polymerase, for repli 
cation ?delity. The PCR product was treated with Dpn I 
endonuclease to digest the parental DNA template. Modi?ed 
plasmid DNA was transformed into Escherichia coli, ampli 
?ed, and puri?ed. The DNA sequences of the mutants were 
con?rmed by DNA sequencing. BChE mutants were 
expressed in human embryonic kidney cell line 293T/ 17. 
Cells were grown to 80-90% con?uence in 6-well dishes and 
then transfected by Lipofectamine 2000 complexes of 4 pg 
plasmid DNA per each well. Cells were incubated at 37° C. in 
a C02 incubator for 24 hours and cells were moved to 60-mm 
culture vessel and cultured for four more days. The culture 
medium [10% fetal bovine serum in Dulbecco’s modi?ed 
Eagle’ s medium (DMEM)] was harvested for a BChE activity 
assay. To measure cocaine and benzoic acid, the product of 
cocaine hydrolysis by BChE, we used sensitive radiometric 
assays based on toluene extraction of [3H] cocaine labeled on 
its benzene ring were used in accordance with Masson, P.; 
Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, 
C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, 
herein incorporated by reference. In brief, to initiate reac 
tions, 100 nCi of [3H]cocaine was mixed with 100 pl of 
culture medium. Reactions proceeded at 370 C. for varying 
times. Reactions were stopped by adding 300 pl of 0.02 M 
HCl, which neutralized the liberated benzoic acid while 
ensuring a positive charge on the residual cocaine. [3H]ben 
zoic acid was extracted by 1 ml of toluene and measured by 
scintillation counting. Finally, the measured time-dependent 
radiometric data were ?tted to the kinetic equation so that the 
catalytic ef?ciency (km/KM) was determined. 
Depicted in FIG. 1 are plots of some important distances in 
the MD-simulated (—)-cocaine binding with A328W/Y 332G 
BChE versus the simulation time, along with root-mean 
square deviation (RMSD) of the coordinates of backbone 
atoms in the simulated structure from those in the X-ray 
crystal structure. MD trajectories for other complexes were 
similar to these two in FIG. 1, although the simulated average 
distances are different. Summarized in Table 2 are the average 
values of some important geometric parameters in the simu 
lated complexes. 
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TABLE 2 
0 Average values of the geometric parameters 
BChE—cocaine binding“ <D1>,mn <D1> <D2> <D3> <D4> <®> 
wild-type 5.60 3.27 5.77 2.71 3.37 67 
wild—type with (+)—cocainel7 7.64 3.69 2.88 3.30 2.83 61 
A328W/Y332A 7.11 3.87 3.30 2.14 3.01 51 
A328W/Y332G 7.06 3.96 2.28 2.52 2.42 60 
A328W/Y332A/Y419S 5.18 5.84 5.64 4.56 6.97 164 
RMSDd 
nonpre pre 
1.14 1.27 
1.15 1.13 
1.58 1.65 
1.20 1.35 
2.66 2.62 
“Refers to (—)-cocaine binding with wild-type human 
BChE or (—)-cocaine binding with a mutant BChE, unless 
indicated otherwise. 
[Refers to (+)-cocaine binding with wild-type human 
BChE. 
C<D1>n0n and <D1> represent the average distances 
between the S198 OY atom and the carbonyl carbon of the 
cocaine benzoyl ester in the simulated non-prereactive and 
prereactive BChE-cocaine complexes, respectively. <D2>, 
<D3>, <D4> refer to the average values of the simulated 
distances from the carbonyl oxygen of the cocaine benzoyl 
ester to the NH hydrogen atoms of G116, G117, and A199 
residues, respectively. <®> is the average value of the dihe 
dral angle formed by the S198 OY atom and the plane of the 
carboxylate group of the cocaine benzoyl ester. See Scheme 
2. 
“The root-mean-square deviation (RMSD) of the coordi 
nates of backbone atoms in the simulated structure from those 
in the X-ray crystal structure of BChE. “nonpre” and “pre” 
refer to the non-prereactive and prereactive BChE-cocaine 
complexes, respectively. 
(—)- and (+)-Cocaine Binding with Wild-Type BChE. 
FIG. 2 shows the binding structures of the simulated non 
prereactive and prereactive complexes of wild-type BChE 
binding with the two enantiomers of cocaine. In the non 
prereactive complexes with (—)- and (+)-cocaine, the methyl 
ester group of cocaine is positioned at the top of the H438 
backbone, while the cocaine benzoyl ester moiety is quasi 
parallel to the CiOY side chain of S 1 98 with a dihedral angle 
6) of —80 and 140°, respectively. 
Scheme 2. Hydrolysis of (—)-cocaine and (+)-cocaine. 
Here, 6) refers to the dihedral angle formed by S198 0V and 
the plane of carboxylate group of the cocaine benzoyl ester as 
shown in the structure diagram below. 
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The simulated internuclear distances between the carbonyl 
oxygen of cocaine benzoyl ester group and the NH hydrogen 
of G1 16, G117, and A199 are comparable for the two enan 
tiomers. The simulated average distances between the carbo 
nyl carbon of the benzoyl ester and S198 OY are 5.60 A and 
5.18 A for (—)- and (+)-cocaine, respectively. Comparing the 
simulated protein backbone structures to the X-ray crystal 
structure of Nicolet et a1, one can see from FIG. 1 that the 
RMSD values are all smaller than 1.3 A for the whole protein 
structures. 
The MD simulations of the prereactive complexes reveal 
that wild-type BChE binding with (—)-cocaine is essentially 
the same as the binding with (+)-cocaine in the binding site, 
except for the different positions of methyl ester group of the 
substrates. The simulated average distances between the car 
bonyl carbon of the benzoyl ester and S198 OY are 3.27 and 
3.69 A for (—)-cocaine and (+)-cocaine, respectively. More 
over, the (+)-cocaine is stabilized more effectively by the 
formation of strong hydrogen bonds with the backbone NH of 
residues G116, G117, and A199 as summarized above in 
Table 2. The cocaine benzoyl ester moiety is positioned quasi 
perpendicular to S198 C40Y with a dihedral angle 6 of ~670 
and ~61o for (—)- and (+)-cocaine, respectively. 
A comparison was made between the currently simulated 
structures of the BChE-cocaine binding with those simulated 
previously by using a homology model of BChE and it was 
noted that two major differences between the two sets of 
structures. By using the X-ray crystal structure in accordance 
with Nicolet et al, the acyl loop is positioned on the top of the 
cocaine benzoyl ester moiety of the cocaine, whereas the acyl 
loop is far from the cocaine benzoyl ester moiety in the 
structure simulated starting from the homology model of 
Zhan et al. The RMSD of the coordinates of backbone atoms 
in the previously simulated prereactive BChE-(—)-cocaine 
complex from those in the X-ray crystal structure of BChE is 
~2.0 A for the entire protein and ~3 .0 A for the acyl loop. The 
RMSD value became ~2.4 A for the entire protein and ~3.3 A 
for the acyl loop, when the X-ray crystal structure was 
replaced by the MD-simulated prereactive BChE-(—)-cocaine 
complex starting from the X-ray crystal structure. Despite 
these structural differences, the benzoyl ester group of the 
ligand is still close to the key residues (S197, G116, and 
G1 17) in the BChE binding site. Some signi?cant differences 
are associated with the distances between the S198 OY atom 
and the carbonyl carbon of the cocaine benzoyl ester in non 
prereactive complexes. The average values of this distance in 
the non-prereactive complexes were ~9.5 and ~8.5 A for (—) 
and (+)-cocaine, respectively, when a homology model was 
used. Using the X-ray crystal structure to conduct the analy 
sis, corresponding average values became ~5.6 and ~5.2 A, 
respectively. Therefore, both (—)- and (+)-cocaine became 
closer to the binding site when the homology model was 
replaced by the X-ray crystal structure. However, no signi? 
cant changes of the binding in the prereactive complexes were 
observed when the used homology model was replaced by the 
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X-ray crystal structure. The average values of the simulated 
distance between the S198 OY atom and the carbonyl carbon 
of the cocaine benzoyl ester in the prereactive complexes are 
always close to ~3 .5 A for both (—)- and (+)-cocaine no matter 
whether the X-ray crystal structure or homology model of 
BChE was used as the starting structure. The similar compu 
tational results obtained from the use of the X-ray crystal 
structure and homology model of BChE provides evidence 
that the fundamental structural and mechanistic insights 
obtained from the previous computational studies of Zhan et 
al are reliable, despites the previous simulations were per 
formed by using the homology model when the X-ray crystal 
structure was not available. 
Further, the simulated structures of the non-prereactive 
BChE-cocaine complexes were superimposed with the cor 
responding prereactive complexes. As shown in FIG. 3, the 
(—)-cocaine rotation in the BChE active site from the non 
prereactive complex to the prereactive complex is hindered 
by some residues as the positions on332, A328, and F329 
residues in the non-prereactive complex are signi?cantly dif 
ferent from the corresponding positions in the prereactive 
complex, whereas none of these residues hinders the (+) 
cocaine rotation in the BChE active site from the non-prere 
active complex to the prereactive complex because these resi 
dues stay in nearly the same positions in the two BChE-(+) 
cocaine complexes. 
(—)-Cocaine Binding with BChE Mutants. 
Now that the (—) -cocaine rotation from the non-prereactive 
complex to the prereactive complex has been known to be the 
rate-determining step of the BChE-catalyzed hydrolysis of 
(—)-cocaine as shown by Zhan et al, useful BChE mutants 
should be designed to speci?cally accelerate the change from 
the non-prereactive BChE-(—)-cocaine complex to the prere 
active complex. The question is whether MD simulation can 
be performed to help design BChE mutants that have higher 
catalytic activity for (—)-cocaine hydrolysis. 
In the simulated non-prereactive complex, the average dis 
tance between the carbonyl carbon of cocaine benzoyl ester 
and S198 0V is 7.6 A forA328W/Y332A BChE and 7.1 A for 
A328W/Y 332G BChE, as seen in Table 2 above. In the simu 
lated prereactive complex, the average values of this impor 
tant internuclear distance become 3.87 and 3.96 A for 
A328W/Y 332A and A328W/Y 332G BChE’s, respectively. 
Compared to the simulated wild-type BChE-(—)-cocaine pre 
reactive complex, the average distances between the carbonyl 
carbon of the cocaine benzoyl ester and S198 0V in the pre 
reactive complex of (—)-cocaine with A328W/Y332A and 
A328W/Y 332G BChE’s are all slightly longer, whereas the 
average distances between the carbonyl oxygen of the 
cocaine benzoyl ester and the NH of G1 16, G117, and A199 
residues are all shorter. This provides evidence that (—)-co 
caine more strongly bind with A328W/Y332A and A328W/ 
Y332G BChE’s in the prereactive complexes. More impor 
tantly, the (—)-cocaine rotation in the active site of A328W/ 
Y332A and A328W/Y332G BChE’s from the non 
prereactive complex to the prereactive complex did not cause 
considerable changes of the positions of A332 (or G332), 
W328, and F329 residues as seen in FIG. 4, compared to the 
(—)-cocaine rotation in the active site of wild-type BChE. 
These results provide evidence that A328W/Y 332A and 
A328W/Y 332G BChE’s should be associated with lower 
energy barriers than the wild-type for the (—) -cocaine rotation 
from the non-prereactive complex to the prereactive complex. 
Further, (—)-cocaine binding with A328W/Y 332G BChE is 
very similar to the binding with A328W/Y 332A BChE, but 
the position change of F329 residue caused by the (—)-cocaine 
rotation was signi?cant only in A328W/Y 332A BChE, thus 
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suggesting that the energy barrier for the (—)-cocaine rotation 
in A328W/Y 332G BChE should be slightly lower than that in 
A328W/Y332A BChE. 
Concerning (—)-cocaine binding with A328W/Y332A/ 
Y419S BChE,Y419 stays deep inside the protein and does not 
directly contact with the cocaine molecule. The Y4 1 9S muta 
tion was tested because it was initially expected that this 
mutation would further increase the free space of the active 
site pocket so that the (—)-cocaine rotation could be easier. 
However, as seen in Table 2 above, the average distance 
between the carbonyl carbon of cocaine benzoyl ester and 
S198 OY atom in the simulated prereactive complex was as 
long as 5.84 A. The average distances between the carbonyl 
oxygen of the cocaine benzoyl ester and the NH hydrolysis 
atoms of G116, G117, and A199 residues are between 4.56 
and 6.97 A; no any hydrogen bond between them. In addition 
to the internuclear distances, another interesting geometric 
parameter is the dihedral angle, 6), formed by S198 0V and the 
plane of the carboxylate group of the cocaine benzoyl ester. 
As seen in Table 2, the 6) values in the prereactive complexes 
of cocaine with wild-type BChE and all of the BChE mutants 
other than A328W/Y332A/Y419S BChE all slightly deviate 
from the ideal value of 90° for the nucleophilic attack of S 1 98 
0V at the carbonyl carbon of cocaine. The 6) value in the 
prereactive complex of (—)-cocaine with A328W/Y332A/ 
Y419S BChE is 164°, which is considerably different from 
the ideal value of 90°. 
Catalytic Activity. 
The aforementioned discussion provides evidence that the 
energy barriers for the (—)-cocaine rotation in A328W/ 
Y332A and A328W/Y 332G BChE’s from the non-prereac 
tive complex to the prereactive complex, the rate-determining 
step for the BChE-catalyzed hydrolysis of (—)-cocaine, 
should be lower than that in the wild-type BChE. Thus, the 
MD simulations predict that both A328W/Y 332A and 
A328W/Y332G BChE’ s should have a higher catalytic activ 
ity than the wild-type BChE for (—)-cocaine hydrolysis. Fur 
ther, the MD simulations also suggest that the energy barrier 
for the (—)-cocaine rotation in A328W/Y332G BChE should 
be slightly lower than that in A328W/Y332A BChE and, 
therefore, the catalytic activity of A328W/Y332G BChE for 
the (—)-cocaine hydrolysis should be slightly higher than the 
activity of A328W/Y 332A BChE. In addition, the MD simu 
lations predict that A328W/Y332A/Y419S BChE should 
have no catalytic activity, or have a considerably lower cata 
lytic activity than the wild-type, for (—)-cocaine hydrolysis 
because (—)-cocaine binds with the mutant BChE in a way 
that is not suitable for the catalysis. 
The catalytic ef?ciency (km/KM) of A328W/Y 332A 
BChE for (—)-cocaine hydrolysis was reported to be 8.56><106 
M min—l, which is 9.39 times ofthe kcat/KMvalue (9.11><105 
M min—l) of the wild-type BChE. To examine these theoreti 
cal predictions of the relative activity forA328W/Y 332G and 
A328W/Y332A/Y419S BChE’s, aA328W/Y332A, A328W/ 
Y332G, and A328W/Y332A/Y419S BChE was produced 
through site-directed mutagenesis. To minimize the possible 
systematic experimental errors of the kinetic data, kinetic 
studies were performed with all of three mutants under the 
same condition and compared the catalytic ef?ciency of the 
A328W/Y332G and A328W/Y332A/Y419S to that of the 
A328W/Y332A for (—)-cocaine hydrolysis at benzoyl ester 
group. Based on the kinetic analysis of the measured time 
dependent radiometric data, the ratio of the kcat/KM value of 
A328W/Y332G BChE to the kcat/KM value of A328W/ 
Y332A BChE for the (—)-cocaine hydrolysis was determined 
to be ~2.08, or A328W/Y332G BChE has a kcat/KM value of 
~1.78><107 M min“ 1 for the (—) -cocaine hydrolysis. The radio 
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metric data show no signi?cant catalytic activity forA328W/ 
Y332A/Y419S BChE. These experimental data are consis 
tent with the theoretical predictions based on the MD 
simulations. 
Conclusion. 
Molecular modeling, molecular docking, and molecular 
dynamics (MD) simulations were performed to study cocaine 
binding with human butyrylcholinesterase (BChE) and its 
mutants, based on a recently reported X-ray crystal structure 
of human BChE. The MD simulations of cocaine binding 
with wild-type BChE led to average BChE-cocaine binding 
structures similar to those obtained recently from the MD 
simulations based on a homology model of BChE, despite the 
signi?cant difference found at the acyl binding pocket. This 
con?rms the fundamental structural and mechanistic insights 
obtained from the prior computational studies of Zhan et al 
based on a homology model of BChE, e.g., the rate-determin 
ing step for BChE-catalyzed hydrolysis of biologically active 
(—)-cocaine is the (—)-cocaine rotation in the BChE active site 
from the non-prereactive BChE-(—)-cocaine complex to the 
prereactive complex. 
The MD simulations further reveal that the (—)-cocaine 
rotation in the active site of wild-type BChE from the non 
prereactive complex to the prereactive complex is hindered 
by some residues such that the positions of Y332, A328, and 
F329 residues in the non-prereactive complex are signi? 
cantly different from those in the prereactive complex. Com 
pared to (—)-cocaine binding with wild-type BChE, (—)-co 
caine more strongly bind with A328W/Y332A and A328W/ 
Y332G BChE’s in the prereactive complexes. More 
importantly, the (—)-cocaine rotation in the active site of 
A328W/Y 332A and A328W/Y332G BChE’s from the non 
prereactive complex to the prereactive complex did not cause 
considerable changes of the positions of A332 or G332, 
W328, and F329 residues. These results provide evidence that 
A328W/Y332A and A328W/Y332G BChE’s are associated 
with lower energy barriers than wild-type BChE for the (—) 
cocaine rotation from the non-prereactive complex to the 
prereactive complex. Further, (—)-cocaine binding with 
A328W/Y 332G BChE is very similar to the binding with 
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A328W/Y332A BChE, but the position change of F329 resi 
due caused by the (—)-cocaine rotation was signi?cant only in 
A328W/Y332A BChE, thus suggesting that the energy bar 
rier for (—)-cocaine rotation in A328W/Y332G BChE should 
be slightly lower than that in A328W/Y 332A BChE. It has 
also been demonstrated that (—)-cocaine binds with A328W/ 
Y332A/Y419S BChE in a way that is not suitable for the 
catalysis. 
Based on the computational results, both A328W/Y 332A 
and A328W/Y 332G BChE’s have catalytic activity for (—) 
cocaine hydrolysis higher than that of wild-type BChE and 
the activity of A328W/Y 332G BChE should be slightly 
higher than that of A328W/Y 332A BChE, whereas A328W/ 
Y332A/Y419S BChE is expected to lose the catalytic activ 
ity. The computational predictions are completely consistent 
with the experimental kinetic data, providing evidence that 
the used computational protocol, including molecular mod 
eling, molecular docking, and MD simulations, is reliable in 
prediction of the catalytic activity of BChE mutants for (—) 
cocaine hydrolysis. 
Experiment 2 
MD Simulations and Quantum 
Mechanical/Molecular Mechanical (QM/MM) 
Calculations Relating to Al 995/A328W/Y 332G 
Mutant (Mutant l) (SEQ ID NO: 1) 
Generally speaking, for rational design of a mutant enzyme 
with a higher catalytic activity for a given substrate, one needs 
to design a mutation that can accelerate the rate-determining 
step of the entire catalytic reaction process while the other 
steps are not slowed down by the mutation. Reported com 
putational modeling and experimental data indicated that the 
formation of the prereactive BChE-(—) -cocaine complex (ES) 
is the rate-determining step of (—)-cocaine hydrolysis cata 
lyzed by wild-type BChE as disclosed by Sun et al, Zhan et al 
and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys. 
Chem. B 2005, 109, 4776, herein incorporated by reference, 
whereas the rate-determining step of the corresponding (+) 
cocaine hydrolysis is the chemical reaction process consist 
ing of four individual reaction steps disclosed by Zhan et al 
and shown in Scheme 3 and Scheme 4 below. 








































